SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 7.59% Stake in Kura Oncology

Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 7.59% in Kura Oncology, Inc., totaling 6,572,000 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Kura Oncology, Inc.
• The filing indicates that the Reporting Persons beneficially own an aggregate of 6,572,000 shares of Kura Oncology, Inc. Common Stock.
• This ownership represents 7.59% of Kura Oncology, Inc.'s outstanding common stock, based on 86,574,687 shares outstanding as of April 28, 2025.
• Armistice Capital, LLC, a Delaware entity, is the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the securities held by the Master Fund.
• Both Armistice Capital, LLC and Steven Boyd hold shared voting and shared dispositive power over all 6,572,000 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual report of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing indicates a significant stake by an institutional investor in Kura Oncology, Inc., a biotechnology company. Such filings are common and reflect investment decisions by funds based on their analysis of a company's prospects within its sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor like Armistice Capital may be viewed positively by other shareholders as a vote of confidence, or it could signal potential future activist interest, although the filing states the shares were not acquired for control purposes.

Key Dates

Keywords

Kura Oncology, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals